Key Points: Biomarkers can be used for risk assessment, detection, diagnosis, and prognosis and to personalize treatment in lung cancer. Clinically useful biomarkers for selection of high-risk patients for lung cancer screening and to differentiate early lung cancer from benign pulmonary nodules are needed. Biomarkers for nodule management and determination of high-risk groups for lung cancer screening are at all phases of development, from discovery to clinical utility studies. Current trends in lung cancer biomarker development include the integration of clinical and radiologic features with molecular biomarkers, the application of artificial intelligence to molecular and imaging biomarker development, the use highly sensitive technologies such as next-generation sequencing for molecular exploration, and a commitment to high-quality clinical validation and utility studies. READ ARTICLE
Clinics in Chest Medicine. DOI: 10.1016/j.ccm.2019.10.004
Authors: Catherine R. Sears, Peter J. Mazzone